RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS

6 Months Ended

Nov. 30, 2021

Prior Period Adjustment [Abstract]

Error Correction [Text Block]

NOTE 8:  RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS

During September 2021, the Company determined that errors were included in the previously issued financial statements as described below. As a result, we restated our financial statements for the periods ended November 30, 2020.

The Company discovered the errors listed below. The restatement corrects these errors.

Our non-cash stock-based compensation expenses calculation applied forfeiture adjustments to both vested and unvested outstanding options, including those for which the employee had provided the requisite service and vesting had occurred, which resulted in an understatement of stock compensation expense. Additionally, our calculation expensed all issued options at vesting dates versus pro- rata over the period the requisite service was provided.

Stock-based compensation expense shown on the statement of operations is a non-cash expense, and impacts accumulated deficit and additional paid-in capital on the balance sheet. However, this does not impact the Company’s cash, revenues or other aspects of ongoing operations.

The restatement for the quarter ended November 30, 2020 resulted in no changes in the provision for income taxes.

The effect of the restatement on the consolidated statement of operations for the three months ended November 30, 2020 is as follows:

	As Previously Reported		Adjustments		As Restated
Cost of sales	$	1,011,030	$	52,777	$	1,063,807
Gross Profit		361,496		(52,777)		308,719
Operating Expenses:
Selling, general and administrative		1,254,847		149,999		1,404,846
Research and development		586,403		30,158		616,561
Total operating expense		1,841,250		180,157		2,021,407
Loss from operations		(1,479,754)		(232,934)		(1,712,688)
Loss before income taxes		(1,471,771)		(232,934)		(1,704,705)
Net loss	$	(1,485,164)	$	(232,934)	$	(1,718,098)
Basic net loss per common share	$	(0.13)	$	(0.02)	$	(0.15)
Diluted net loss per common share	$	(0.13)	$	(0.02)	$	(0.15)

The effect of the restatement on the consolidated statement of operations for the six months ended November 30, 2020 is as follows:

	As Previously Reported		Adjustments		As Restated
Cost of sales	$	1,971,960	$	117,564	$	2,089,524
Gross Profit		544,372		(117,564)		426,808
Operating Expenses:
Selling, general and administrative		2,419,411		291,379		2,710,790
Research and development		1,261,096		66,970		1,328,066
Total operating expense		3,680,507		358,349		4,038,856
Loss from operations		(3,136,135)		(475,913)		(3,612,048)
Loss before income taxes		(3,120,061)		(475,913)		(3,595,974)
Net loss	$	(3,134,579)	$	(475,913)	$	(3,610,492)
Basic net loss per common share	$	(0.27)	$	(0.04)	$	(0.31)
Diluted net loss per common share	$	(0.27)	$	(0.04)	$	(0.31)
Comprehensive loss	$	(3,137,829)	$	(475,913)	$	(3,613,742)

The effect of the restatement on the consolidated statement of cash flows for the period ended November 30, 2020 is as follows:

	As Previously Reported		Adjustments		As Restated
Cash flows from operating activities:
Net loss	$	(3,134,579)	$	(475,913)	$	(3,610,492)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock option expense		24,227		475,913		500,140
Net cash used in operating activities		(2,880,218)		-		(2,880,218)
Cash and cash equivalents at end of period	$	5,683,787	$	-	$	5,683,787